Table 2

Meta-analysis summary statistics for the most significantly associated variants with maximal site of JSN and with bone remodelling response phenotypes of hip OA

Study characteristics SNP characteristics Meta-analysis Sex-adjusted meta-analysis
Cases definitionControls definitionN
case/control
SNPChrPosition
(b37)
Nearest
gene(s)
EAEAF
case/control
OR
(95% CI)
p ValueOR
(95% CI)
p Value
Hip OA with superior JSNHip OA with non-superior JSN1469/649rs7541061347 152 655 LRCH1 T0.51/0.600.70 (0.61 to 0.80)1.49×10−7 0.72 (0.62 to 0.82)2.17×10−6
Hip OA with axial/medial JSNHip OA with non-axial/medial JSN501/1617rs7541061347 152 655 LRCH1 T0.61/0.521.47 (1.27 to 1.70)3.66×10−7 1.42 (1.22 to 1.65)6.92×10−6
Hip OA with superior JSNHip OA with non-superior JSN1469/649rs730235632181 502 830 CWC22
UBE2E3
T0.21/0.141.59 (1.33 to 1.91)6.59×10−7 1.58 (1.31 to 1.90)1.65×10−6
Hip OA with axial/medial JSNHip OA with non-axial/medial JSN501/1617rs730235632181 502 830 CWC22
UBE2E3
T0.14/0.200.61 (0.50 to 0.75)2.03×10−6 0.62 (0.50 to 0.76)5.44×10−6
Hip OA with axial/medial JSNHip OA with non-axial/medial JSN501/1617rs170507274121 426 827 PRDM5 T0.18/0.121.65 (1.35 to 2.01)6.87×10−7 1.67 (1.36 to 2.05)8.38×10−7
Hip OA with hypertrophic responseHip OA with non-hypertrophic response637/1481rs6766414331 488 222 STT3B
GADL1
G0.29/0.221.45 (1.24 to 1.69)3.13×10−6 1.46 (1.25 to 1.70)2.31×10−6
Hip OA with hypertrophic responseHip OA with non-hypertrophic response637/1481rs618378811223 626 562 CAPN8
C1orf65
C0.29/0.221.44 (1.23 to 1.68)4.56×10−6 1.43 (1.23 to 1.67)5.55×10−6
  • EA, effect allele; EAF, effect allele frequency; JSN, joint space narrowing; OA, osteoarthritis; SNP, single nucleotide polymorphism.